GENE1:1
Latest round
- Seed
Last raised
- Nov 2022
Total raised
- $0M
Investors
- 1
About GENE1:1
, dba GENE1:1, operates as a provider of intestinal microbe diagnostic services and products. As of February 2023, Jinyoung Lee serves as the CEO of the company., Ltd. The company provides digital healthcare based on both beneficial and toxic bacteria (microbiomes) of intestinal microbes. The firm offers mental health microbes such as phacalibacterium, flavonifractor, coprococcus, dialister, blautia, and permicutes. The company also offers a service that recommends supplements and meal plans based on intestinal microbial tests. GENE1:1’s partners include Futureplay, Future’s Lab, Geninus, MLAI, and more.
Who invested in GENE1:1
1 investor across 2 rounds
See all investors in GENE1:1
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about GENE1:1
Who invested in GENE1:1?
GENE1:1 has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GENE1:1 raised?
GENE1:1 has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did GENE1:1 last raise money?
GENE1:1's most recent round on record is a Seed, in Nov 2022.
What does GENE1:1 do?
, dba GENE1:1, operates as a provider of intestinal microbe diagnostic services and products.
Where is GENE1:1 headquartered?
GENE1:1 is headquartered in Seoul, South Korea.
Which VCs invest in companies like GENE1:1?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, MPCi, Zijin Venture Capital and Legend Capital back healthcare companies at GENE1:1's stage. Their profiles are linked below.
VCs backing healthcare startups at Seed
Raising like GENE1:1? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.